Iothalamic Acid
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
928623-31-8- Standard-SMILES
CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I- InChIKey
UXIGWFXRQKWHHA-UHFFFAOYSA-N- Summenformel
- C11.H9.I3.N2.O4
- Durchschnittliche Molmasse
- 613,91 g/mol
Überblick
Iotalamic acid is an organic molecular entity.
Namen und Bezeichner
- Bevorzugter Name
- Iothalamic Acid
- IUPAC
- 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
- Englischer Name
- IothalaMic Acid-d3
- Summenformel
- C11H9I3N2O4
- Molmasse
- 613.91357
Namen und Synonyme
iotalamic acidIOTHALAMIC ACID2276-90-63-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acidAcido iotalamicoAcide iotalamiqueAcidum iotalamicumMI-21616CHD79MIXNSC-759891DTXSID5023164Benzoic acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)-
Weitere Namen anzeigen
IothalaMic Acid-d3[2H3]-Iothalamic Acid2,4,6-triiodo-3-(methylcarbamoyl)-5-[(2,2,2-trideuterioacetyl)amino]benzoic acid
Acid, IotalamicAngioConrayAngio ConrayAcid, IothalamicAcid, MethalamicIothalamate, SodiumRefChem:56855DTXCID903164
Datenbank-Bezeichner
- CAS
928623-31-8- ChEMBL
CHEMBL1201300- ChEBI
CHEBI:31713- UNII
- 16CHD79MIX
- EC Number
- 218-897-4
- Nikkaji
- J7.384I
Eigenschaften
Berechnete StruktureigenschaftenWird ergänzt
- XLogP
- 1,9
- Polarare Oberfläche (TPSA)
- 95,5 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 4
- Frei drehbare Bindungen
- 3
- Schwere Atome
- 20
- Formalladung
- 0
- Komplexität
- 420
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals
LogP-1.15
Human DrugsBreast Feeding; Lactation; Milk, Human; Diagnostic Media; Contrast Agents
Physikochemische Eigenschaften
- Schmelzpunkt
- 287 °C · >287°C (dec.)
- storage temp.
- Refrigerator
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly, Sonicated)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS ClassificationNot Classified
Gefahrenhinweise
Regulatory InformationStatus: Active Update: 27-10-2014 https://echa.europa.eu/registration-dossier/-/registered-dossier/12157
Other Safety InformationIMAP assessments - Benzoic acid, 3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]-: Environment tier I assessment
Hazard Classes and CategoriesNot Classified
Sicherheit und Schutzausrüstung
Protective Action Criteria (PAC)
70 [mg/m3]
770 [mg/m3]
4600 [mg/m3]
Toxikologische Informationen
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Chemie und Industrie
Pharmakologische Informationen
ATC Code
V - Various
QV - Various
Protein BindingIothalamate salts are poorly bound to serum albumin.
Biological Half-LifeIn patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively.
FDA Pharmacological Classification
16CHD79MIX
IOTHALAMIC ACID
Established Pharmacologic Class [EPC] - Radiographic Contrast Agent
Mechanisms of Action [MoA] - X-Ray Contrast Activity
Iothalamic acid is a Radiographic Contrast Agent. The mechanism of action of iothalamic acid is as a X-Ray Contrast Activity.
MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion
Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods.
Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases.
Verwendung und Herstellung
UsesUse (kg; approx.) in Germany (2009): >500
Anwendungen
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…